Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. This is a Japan Extension Study of Global Study MK-3475-189 (NCT02578680).
Keynote 189 trial#
10.1097/JTO.Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Gadgeel, MD, MBBS, professor, University of Michigan Medicine, discusses the updated results of the phase III KEYNOTE-189 trial in metastatic nonsquamous non-small cell lung cancer (NSCLC). Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. This study is the first active-control trial that enrolled patients on the basis of. Roy Herbst, MD, PhD: KEYNOTE-189 is an important study because it took pembrolizumab, which we know can be used as a single agent in people who are. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. We present results of KEYNOTE-010, the first randomised comparison of pembrolizumab 2 mg/kg or 10 mg/kg every 3 weeks versus standard-of-care treatment for PD-L1-positive non-small-cell lung cancer that progressed after at least platinum-based chemotherapy. Nondriver NSCLC Trials: KEYNOTE-189, -407, -024. Outcomes among patients with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab plus pemetrexed-platinum: results from the KEYNOTE-189 study. Merck announced results from KEYNOTE-189, a pivotal Phase 3 trial evaluating KEYTRUDA®, Merck’s anti-PD-1 therapy, in combination with pemetrexed and cisplatin or carboplatin for the first-line. There was 2:1 randomization of that same combination versus standard pemetrexed and carboplatin. 1 day tickets are 115 and 2 day tickets are 189. KEYNOTE-189 was the follow-up randomized phase III trial. Shirish Gadgeel, Delvys Rodríguez-Abreu, Giovanna Speranza, Emilio Esteban, Enriqueta Felip, Manuel Dómine, Rina Hui, Maximilian J. There will also be keynote speakers such as Lord John Lee, Andy Brough, Leon Boros, Clarke Carlisle.
Garassino MC, Gadgeel S, Esteban E, et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. KEYNOTE-189: Rate of Kidney Toxicity in Patients With NSCLC NovemNino Balanchivadze, MD, FACP, discuses the rates of acute kidney injury in the KEYNOTE-189 study, which evaluated pembrolizumab and carboplatin/pemetrexed in patients with metastatic nonsmall cell lung cancer. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Gadgeel S, Rodríguez-Abreu D, Speranza G, et al.
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. International Association for the Study of Lung Cancer. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Keynote 189: Tumor mutational burden not significantly associated with efficacy of pembrolizumab.
0 kommentar(er)
